Clinuvel Pharmaceuticals

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Trading Performance

Average Directional Index

Score

-1.65

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 6 74.2 0.83% 5.00% 13.3% -3.8% 62.8%
SHORT 5 49.8 0.00% 0.00% 0.0% -17.2% -85.9%

Summary

Technical Analysis

Clinuvel Pharmaceuticals (CUV.AX)


Indicator:

AVG DIRECTIONAL INDEX


Last Signal:

MEDIUM TREND


Trading: HOLD @ $32.61
Signal Strength: MEDIUM
Recommendation:

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has been constructed to highlight the existence of a trend for an assocaited timeframe. Trend determining indicators can be used in short, medium or long term timeframes & determines if the stock is trending or ranging. Once the trend status is quantified, this can then be coupled to additional indicators to add a significant advantage to the trading strategy.


Clinuvel Pharmaceuticals (ASX:CUV) has confirmed a strong trend is present. Clinuvel Pharmaceuticals has an ATR(14) of 1.608, a DX of 36.19 & an ADX(14) of 27.06



The Average Directional Index (ADX) Minus Directional Indicator (-DI) and Plus Directional Indicator (+DI) represent a group of directional movement indicators that form a trading system developed by Welles Wilder.

Calculation: Average Directional Movement Index (ADX):
Trend Strength ;
1) 0-25 = Absent or Weak Trend;
2) 25-50 = Strong Trend;
3) 50-75 = Very Strong Trend;
4) 75-100 Extremely Strong Trend;


PROFILE: Clinuvel Pharmaceuticals (CUV.AX)


Stock Exchange: ASX
Company: Clinuvel Pharmaceuticals
Ticker Codes: | CUV.AX | ASX:CUV |

About Clinuvel Pharmaceuticals (ASX:CUV):

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of a range of severe skin disorders. Its lead drug compound is SCENESSE, a medicinal photoprotective and repigmentation drug that has completed Phase II and III trials in the United States and Europe, which is used for the prevention of phototoxicity in adults with erythropoietic protoporphyria. The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue that acts as a potent skin protectant; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. It has operations in Europe, the United States, and Singapore. The company is headquartered in Melbourne, Australia.

Top 10:

Average Directional Index

Download
Company Close Change(%) Volume Value Signal
CEN Central Australian Phosphate 6.94 8.3 4,068 35.98 BULLISH
ISX Isignthis 0.6 8.2 4,830,133 43.16 BULLISH
RAP Resapp Health 0.15 7.1 428,520 31.35 BULLISH
EML Emerchants 2.55 6.3 2,216,677 45.02 BULLISH
ADH Adairs 2.06 5.6 1,149,442 27.75 BULLISH
DDR Dicker Data 5.16 4 280,998 38.23 BULLISH
GOR Gold Road Resources 1.1 2.8 3,737,117 33.78 BULLISH
PNC Pioneer Credit 2.63 2.3 96,710 28.71 BULLISH
FWD Fleetwood 1.84 2.2 12,917 25.69 BULLISH
GBT Gbst Holdings 2.7 1.9 44,067 55.45 BULLISH